2024-03-24 00:46:24 ET
Summary
- Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease.
- Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US.
- $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.
Alderya – Overview
Aldeyra ([[ALDX]] or the Company), is a small cap, development-stage biotech company with a portfolio of RASP (reactive aldehyde species) modulating compounds. The lead drug is a topical therapy for dry eye disease, reproxalap, that recently received a complete response letter ((CRL)), a rejection from the FDA. The Company believes it has a clear path to provide additional data and obtain approval for reproxalap in early 2025. The Company also has other oral and intravitreal injection products in earlier stages of development....
Read the full article on Seeking Alpha
For further details see:
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie